Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Citius Pharmaceuticals, Inc. (CTXR)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.9400-0.0900 (-4.43%)
At close: 4:00PM EDT
1.9500 +0.01 (+0.52%)
After hours: 07:44PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close2.0300
Open1.9900
Bid1.9400 x 2200
Ask1.9500 x 36900
Day's Range1.8600 - 2.0000
52 Week Range0.8730 - 4.5600
Volume7,065,253
Avg. Volume2,587,159
Market Cap262.82M
Beta (5Y Monthly)1.53
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • PR Newswire

    Citius Pharmaceuticals to Host Investor Webcast to Discuss the Acquisition of Late Phase 3 Cancer Immunotherapy I/ONTAK (E7777)

    Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR) today announced that it will host a webcast on October 20, 2021 at 8:30 a.m. ET to discuss the Company's previously announced acquisition of I/ONTAK (E7777), an improved formulation of immunotoxin ONTAK®, which was previously approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma (CTCL).

  • PR Newswire

    Citius Pharmaceuticals to Present at Upcoming October Investor Conferences

    Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products with a focus on oncology, anti-infective products in adjunct cancer care, unique prescription products, and stem cell therapies, today announced that it will present at two investor conferences during the month of October 2021.

  • PR Newswire

    Temple University Renames College of Liberal Arts Main Campus Building in Honor of Citius Pharmaceuticals Executive Chairman Leonard Mazur

    Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products with a focus on oncology, anti-infective products in adjunct cancer care, unique prescription products, and stem cell therapies, today announced that Citius Executive Chairman Leonard Mazur and his wife, Helena Mazur, were honored by Temple University, Philadelphia, PA, which renamed the main bu

Advertisement
Advertisement